Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-050587
Filing Date
2025-04-03
Accepted
2025-04-03 17:15:36
Documents
6
Effectiveness Date
2025-04-03

Document Format Files

Seq Description Document Type Size
1 S-8 sabs_s-8_fy25apr.htm S-8 132352
2 EX-5.1 sabs-ex5_1.htm EX-5.1 32867
3 EX-23.1 sabs-ex23_1.htm EX-23.1 3797
4 EX-FILING FEES sabs-exfiling_fees.htm EX-FILING FEES 52987
5 GRAPHIC img84541401_0.jpg GRAPHIC 18837
6 GRAPHIC img84541401_1.jpg GRAPHIC 18837
  Complete submission text file 0000950170-25-050587.txt   275328
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-286368 | Film No.: 25810728
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)